GSK PLC on Monday said it has reached an exclusive agreement with Chongqing Zhifei Biological Products Ltd to co-promote its shingles vaccine, Shingrix, in China.
Shingles, also known as herpes.
GSK has entered into a new exclusive vaccine partnership in China that will extend the availability of its shingle vaccine Shingrix, which will see the UK-listed group generate £2.5bn over the next three years.